I'm LongbridgeAI, I can summarize articles.BeyondSpring highlighted plinabulin's potential in non-squamous NSCLC following PD-1/L1 inhibitor progression. The DUBLIN-3 Phase 3 trial demonstrated a median overall survival of 10.5 months versus 9.4 months for docetaxel (HR 0.82, p=0.0399), with significantly reduced grade 4 neutropenia. A mechanism-enriched subset showed improved survival (HR 0.55). The company plans the confirmatory DUBLIN-4 Phase 3 trial targeting post-PD-1/L1 patients.
- BeyondSpring outlined late-stage plans for plinabulin, positioning it for non-squamous NSCLC following PD-1/L1 inhibitor progression. * DUBLIN-3 Phase 3 (n=559) showed OS HR 0.82; median OS 10.5 months vs 9.4 months for docetaxel; p=0.0399. * Grade 4 neutropenia fell to 22.3% from 43.5% across cycles; exposure-adjusted grade 4 event rate RR 0.55; p<0.0001. * Mechanism-enriched post-hoc subset showed median OS 15.8 months vs 11.7 months; OS HR 0.55. * Planned DUBLIN-4 confirmatory Phase 3 targets post-PD-1/L1 non-squamous NSCLC with PFS of at least 3 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here